Correction to 'Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)' [The Lancet Regional Health – Europe 41 (2024) 100915]

Autor: Pascal Demoly, Mathieu Molimard, Jean-François Bergmann, Bertrand Delaisi, Amandine Gouverneur, Jade Vadel, Cédric Collin, Laurence Girard, Silvia Scurati, Philippe Devillier

Publikováno v: The Lancet Regional Health. Europe, Vol 46, Iss , Pp 101120- (2024)

Externí odkaz: https://doaj.org/article/ce9e63e521824bfa8837e1fa305a6523

Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)Research in context

Autor: Pascal Demoly, Mathieu Molimard, Jean-François Bergmann, Bertrand Delaisi, Amandine Gouverneur, Jade Vadel, Cédric Collin, Laurence Girard, Silvia Scurati, Philippe Devillier

Publikováno v: The Lancet Regional Health. Europe, Vol 41, Iss , Pp 100915- (2024)

Summary: Background: The only disease-modifying treatment currently available for allergic rhinitis (AR) is allergen immunotherapy (AIT). The main objective of the EfficAPSI real-world study (RWS) was to evaluate the impact of liquid sublingual immun

Externí odkaz: https://doaj.org/article/1cf18a041ca64146a66feda95bb63ba1

Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European access academy

Autor: Elaine Julian, Mira Pavlovic, Oriol Sola-Morales, Fabrizio Gianfrate, Mondher Toumi, Heiner C. Bucher, Christian Dierks, Wolfgang Greiner, Peter Mol, Jean-François Bergmann, Tomas Salmonson, Ansgar Hebborn, Mathilde Grande, Antonella Cardone, Jörg Ruof

Publikováno v: Health Economics Review, Vol 12, Iss 1, Pp 1-15 (2022)

Abstract Objectives Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealin

Externí odkaz: https://doaj.org/article/49b7e3fc8c3140c6be0c21e052b00350

Boosted Lopinavir- Versus Boosted Atazanavir-Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries

Autor: Isabel Hurtado, Santiago Pérez-Hoyos, Consuelo Viladés, Adilia Warris, Federico Pulido, Eva Calabuig, Oscar Murillo Rubio, Dimitrios Paraskevis, Julia Del amo, Pablo Barreiro, INMA JARRIN, Arantza Sanvisens, Enrique Bernal Morell, Roberto Muga, Mariona Xercavins, Jean-Francois Bergmann, Aba Mahamat, Ignacio Pérez Valero, DAVID DALMAU, Clifford Leen, Dominique Costagliola, Jim Young, Vicente Soriano, Montserrat Vargas Laguna, Marcela Guevara, Soraya Boucherit, Jesus Castilla, Jean-Marie Michot, José A. Oteo, Maria Jose Amengual, Vicente Boix, Jonathan Sterne, Valerie Delpech, Jane Anderson, Alexandra Montoliu, Esperanza Merino de Lucas, Sophie Matheron, Michael Kozal, Caroline Sabin, André Cabié, Susana Monge, Luis Fernando Lopez.Cortes, Sylvie ABEL, Cedric Arvieux, Félix Gutiérrez, Bart Rijnders, Eulalia Valle-Garay, Juan Berenguer, Carmen Cabellos, Amy Justice, Felipe García, Joaquín Portilla, Mariana Gerschenson

Publikováno v: Clinical infectious diseases, 60(8), 1262-1268. Oxford University Press
Clinical Infectious Diseases
Clinical Infectious Diseases, Oxford University Press (OUP), 2015, 60 (8), pp.1262-1268. ⟨10.1093/cid/ciu1167⟩
Clinical Infectious Diseases, 60(8), 1262-1268. Oxford University Press
Clinical Infectious Diseases, 60, 1262-8
Clinical Infectious Diseases, 60(8), 1262-8. Oxford University Press
Clinical Infectious Diseases, 60, 8, pp. 1262-8

Current clinical guidelines consider regimens consisting of either ritonavir-boosted atazanavir or ritonavir-boosted lopinavir and a nucleoside reverse transcriptase inhibitor (NRTI) backbone among their recommended and alternative first-line antiret

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0a14e9dc8dd797739eba92f150c49b5
https://pure.amc.nl/en/publications/boosted-lopinavir-versus-boosted-atazanavircontaining-regimens-and-immunologic-virologic-and-clinical-outcomes-a-prospective-study-of-hivinfected-individuals-in-highincome-countries(8b28efd7-688f-4a33-ab91-805ae61a9e99).html

Rivaroxaban for thromboprophylaxis in acutely ill medical patients

Autor: Paulo Bettencourt, Oleksii Korzh, Adriaan Dees, Luis Guillermo Uribe, Jean-Francois Bergmann, Matteo Giorgi-Pierfranceschi, Steven A Conrad, Francesco Violi, Karina Jahnz-Różyk, Brian Buck, Corrado Lodigiani, Chaicharn Pothirat, Michel GALINIER, Marc Lambert, Fredrik Schjesvold, Isabelle Quere, Ann Charlotte Laska

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2013, 368 (6), pp.513-23. ⟨10.1056/NEJMoa1111096⟩
New England journal of medicine, 368(6), 513-523. Massachussetts Medical Society

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40aece33cd62bd7065e7571822c8989
https://hal.univ-brest.fr/hal-00933269